Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FUSION PHARMACEUTICALS INC.

(FUSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Cautiously Up Ahead of Thursday's Opening Bell

07/29/2021 | 09:06am EDT


© MT Newswires 2021
All news about FUSION PHARMACEUTICALS INC.
09/02FUSION PHARMACEUTICALS : to Participate in Upcoming Investor Conferences
PR
08/31FUSION PHARMACEUTICALS : Announces Inducement Grants Under Nasdaq Listing Rule 5..
PR
08/26FUSION PHARMACEUTICALS : B. Riley Starts Fusion Pharmaceuticals at Buy with $17 ..
MT
08/18FUSION PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Fusion Pharmaceu..
MT
08/13Fusion Pharmaceuticals Inc. and TRIUMF Announce Expanded R&D Collaboration fo..
CI
08/13FUSION PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Regula..
AQ
08/13FUSION PHARMACEUTICALS : Expands Agreement With Triumf for Actinium Supply Produ..
MT
08/12FUSION PHARMACEUTICALS : and TRIUMF Announce Expanded R&D Collaboration for Acti..
PR
08/12Fusion Pharmaceuticals and Triumf Announce Expanded R&D Collaboration for Act..
CI
08/11WALL STREET STOCK EXCHANGE : The Fed’s transitionary Inflation scenario gets a b..
More news
Analyst Recommendations on FUSION PHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2021 45,2 M - -
Net income 2021 -102 M - -
Net cash 2021 312 M - -
P/E ratio 2021 -3,93x
Yield 2021 -
Capitalization 386 M 386 M -
EV / Sales 2021 1,65x
EV / Sales 2022 37,3x
Nbr of Employees 65
Free-Float 78,2%
Chart FUSION PHARMACEUTICALS INC.
Duration : Period :
Fusion Pharmaceuticals Inc. Technical Analysis Chart | FUSN | CA36118A1003 | MarketScreener
Technical analysis trends FUSION PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,98 $
Average target price 20,25 $
Spread / Average Target 126%
EPS Revisions
Managers and Directors
John Valliant Chief Executive Officer & Director
John J. Crowley Chief Financial Officer
Barbara Gayle Duncan Chairman
Eric Burak Chief Scientific Officer
James J. O'Leary Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
FUSION PHARMACEUTICALS INC.-23.57%386
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850